Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease.
Luke S McLeanWasek FaisalSagun ParakhSteven C KaoCraig R LewisMelvin T ChinMark VoskoboynikMalinda J ItchinsRoss R JennensAdam R BroadTessa A MorrisBenjamin J SolomonPublished in: JCO precision oncology (2022)
There are limited treatment options for LMD in EGFR-positive lung cancer, and osimertinib at a dose of 80 mg daily is an active therapeutic option for these patients.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- tyrosine kinase
- advanced non small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- brain metastases
- single cell
- prognostic factors
- physical activity
- peritoneal dialysis
- cell therapy
- stem cells
- cerebrospinal fluid
- bone marrow
- mesenchymal stem cells